SparingVision, a French biotech company, raised €75m in Series B funding.
The round was co-led by Jeito Capital and the University of Pittsburgh Medical Center Enterprise (UMPCE), with participation from Ysios Capital, 4Bio, Bpifrance and the RD Fund, the venture arm of Foundation Fighting Blindness (FFB).
The company intends to use the funds to advance the development of its lead treatments, SPVN06 and SPVN20, for a new mutation-agnostic approach leading to new treatments in retinitis pigmentosa (“RP”) one of the leading inherited causes of blindness, support first-in-human studies and bring lead assets to clinical validation.
Led by Stéphane Boissel, President, and Chief Executive Officer, SparingVision develops genetic innovative therapies in ophthalmology for the treatment of blinding inherited retinal diseases. It deployed a build-up strategy including: (i) acquiring GAMUT Therapeutics, a French biotechnology company pioneering a unique gene-independent approach for more advanced patients; (ii) signing a strategic collaboration with Intellia Therapeutics (NASDAQ: NTLA), a clinical-stage genome editing company.
Since 2020 and its first round of financing, SparingVision